KR20230172001A - 특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물 - Google Patents

특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물 Download PDF

Info

Publication number
KR20230172001A
KR20230172001A KR1020237039421A KR20237039421A KR20230172001A KR 20230172001 A KR20230172001 A KR 20230172001A KR 1020237039421 A KR1020237039421 A KR 1020237039421A KR 20237039421 A KR20237039421 A KR 20237039421A KR 20230172001 A KR20230172001 A KR 20230172001A
Authority
KR
South Korea
Prior art keywords
ctla4
combination
treatment
itf3756
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039421A
Other languages
English (en)
Korean (ko)
Inventor
지안루카 포사티
플라비오 레오니
피에트로 사무엘 포치
엘리자베타 갈비아티
크리스티앙 스텐퀼러
Original Assignee
이탈파마코 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이탈파마코 에스.피.에이. filed Critical 이탈파마코 에스.피.에이.
Publication of KR20230172001A publication Critical patent/KR20230172001A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237039421A 2021-04-20 2022-04-19 특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물 Pending KR20230172001A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000009926 2021-04-20
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (1)

Publication Number Publication Date
KR20230172001A true KR20230172001A (ko) 2023-12-21

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039421A Pending KR20230172001A (ko) 2021-04-20 2022-04-19 특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물

Country Status (17)

Country Link
US (1) US20240207228A1 (https=)
EP (1) EP4326259A1 (https=)
JP (1) JP2024515100A (https=)
KR (1) KR20230172001A (https=)
CN (1) CN117177745A (https=)
AR (1) AR125356A1 (https=)
AU (1) AU2022262199A1 (https=)
BR (1) BR112023021125A2 (https=)
CA (1) CA3213275A1 (https=)
CL (1) CL2023002894A1 (https=)
CO (1) CO2023013780A2 (https=)
IL (1) IL307649A (https=)
IT (1) IT202100009926A1 (https=)
MX (1) MX2023012030A (https=)
PE (1) PE20242078A1 (https=)
TW (1) TW202308609A (https=)
WO (1) WO2022223543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008346A (es) * 2016-01-11 2019-07-04 Turnstone Lp Terapia de combinación de virus oncológico e inhibidor de punto de control.
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
BR112023021125A2 (pt) 2023-12-12
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
WO2022223543A1 (en) 2022-10-27
AU2022262199A1 (en) 2023-09-21
US20240207228A1 (en) 2024-06-27
CL2023002894A1 (es) 2024-03-15
JP2024515100A (ja) 2024-04-04
AR125356A1 (es) 2023-07-12
TW202308609A (zh) 2023-03-01
IT202100009926A1 (it) 2022-10-20
IL307649A (en) 2023-12-01
CO2023013780A2 (es) 2023-11-10
CN117177745A (zh) 2023-12-05
MX2023012030A (es) 2023-10-24
CA3213275A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US11744822B2 (en) Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
EP4257609A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
KR20230172001A (ko) 특이적 hdac6 억제제와 적어도 하나의 ctla4 체크포인트 억제제를 포함하는 조합물
EP4257132A1 (en) Sik3 inhibitors for treating diseases resistant to death receptor signalling
US20200230247A1 (en) Combination therapies comprising targeted therapeutics
EA050310B1 (ru) Комбинация, содержащая специфический ингибитор hdac6 и по меньшей мере одно антитело к ctla4
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
US20210186978A1 (en) Combination therapy
CA3019391C (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
JP2023516155A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250207

Comment text: Request for Examination of Application